CD47 and plasma cell myeloma: In summary, we screened specific nanobodies against BCMA and CD47 protein from an immunized camel VHH library, and developed a novel allogeneic “off-the-shelf” BCMA/CD47-directed UCAR-T therapy for multiple myeloma.